S&P 500   4,583.81 (+0.76%)
DOW   36,106.04 (+0.14%)
QQQ   390.13 (+1.32%)
AAPL   194.75 (+1.26%)
MSFT   370.19 (+0.38%)
META   326.25 (+2.77%)
GOOGL   136.84 (+5.25%)
AMZN   146.99 (+1.71%)
TSLA   242.87 (+1.46%)
NVDA   462.99 (+1.75%)
NIO   7.49 (-3.35%)
BABA   72.18 (+0.97%)
AMD   125.13 (+7.11%)
T   17.04 (+0.59%)
F   10.82 (+1.22%)
MU   73.59 (+0.63%)
CGC   0.72 (+3.00%)
GE   118.67 (-0.95%)
DIS   92.79 (+1.41%)
AMC   6.82 (+0.44%)
PFE   28.79 (+0.00%)
PYPL   58.28 (-2.10%)
XOM   99.14 (+0.03%)
S&P 500   4,583.81 (+0.76%)
DOW   36,106.04 (+0.14%)
QQQ   390.13 (+1.32%)
AAPL   194.75 (+1.26%)
MSFT   370.19 (+0.38%)
META   326.25 (+2.77%)
GOOGL   136.84 (+5.25%)
AMZN   146.99 (+1.71%)
TSLA   242.87 (+1.46%)
NVDA   462.99 (+1.75%)
NIO   7.49 (-3.35%)
BABA   72.18 (+0.97%)
AMD   125.13 (+7.11%)
T   17.04 (+0.59%)
F   10.82 (+1.22%)
MU   73.59 (+0.63%)
CGC   0.72 (+3.00%)
GE   118.67 (-0.95%)
DIS   92.79 (+1.41%)
AMC   6.82 (+0.44%)
PFE   28.79 (+0.00%)
PYPL   58.28 (-2.10%)
XOM   99.14 (+0.03%)
S&P 500   4,583.81 (+0.76%)
DOW   36,106.04 (+0.14%)
QQQ   390.13 (+1.32%)
AAPL   194.75 (+1.26%)
MSFT   370.19 (+0.38%)
META   326.25 (+2.77%)
GOOGL   136.84 (+5.25%)
AMZN   146.99 (+1.71%)
TSLA   242.87 (+1.46%)
NVDA   462.99 (+1.75%)
NIO   7.49 (-3.35%)
BABA   72.18 (+0.97%)
AMD   125.13 (+7.11%)
T   17.04 (+0.59%)
F   10.82 (+1.22%)
MU   73.59 (+0.63%)
CGC   0.72 (+3.00%)
GE   118.67 (-0.95%)
DIS   92.79 (+1.41%)
AMC   6.82 (+0.44%)
PFE   28.79 (+0.00%)
PYPL   58.28 (-2.10%)
XOM   99.14 (+0.03%)
S&P 500   4,583.81 (+0.76%)
DOW   36,106.04 (+0.14%)
QQQ   390.13 (+1.32%)
AAPL   194.75 (+1.26%)
MSFT   370.19 (+0.38%)
META   326.25 (+2.77%)
GOOGL   136.84 (+5.25%)
AMZN   146.99 (+1.71%)
TSLA   242.87 (+1.46%)
NVDA   462.99 (+1.75%)
NIO   7.49 (-3.35%)
BABA   72.18 (+0.97%)
AMD   125.13 (+7.11%)
T   17.04 (+0.59%)
F   10.82 (+1.22%)
MU   73.59 (+0.63%)
CGC   0.72 (+3.00%)
GE   118.67 (-0.95%)
DIS   92.79 (+1.41%)
AMC   6.82 (+0.44%)
PFE   28.79 (+0.00%)
PYPL   58.28 (-2.10%)
XOM   99.14 (+0.03%)

BioRestorative Therapies Stock Price, News & Analysis (OTCMKTS:BRTX)

$1.81
+0.05 (+2.84%)
(As of 12/6/2023 ET)
Compare
Today's Range
$1.70
$1.89
50-Day Range
$1.58
$2.28
52-Week Range
$1.41
$7.13
Volume
16,542 shs
Average Volume
191,954 shs
Market Capitalization
$8.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

BRTX stock logo

About BioRestorative Therapies Stock (OTCMKTS:BRTX)

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

BRTX Stock Price History

BRTX Stock News Headlines

Best Light Therapy Lamps for 2023
Henry Ford Would NEVER Have Seen This Coming
In 1908, Henry Ford used a metal called vanadium in his Model T cars. Over a century later, automakers still turn to vanadium to make car bodies lighter and stronger. Today, this under-appreciated metal plays the starring role in cutting-edge battery tech set to revolutionize the energy storage market.
Henry Ford Would NEVER Have Seen This Coming
In 1908, Henry Ford used a metal called vanadium in his Model T cars. Over a century later, automakers still turn to vanadium to make car bodies lighter and stronger. Today, this under-appreciated metal plays the starring role in cutting-edge battery tech set to revolutionize the energy storage market.
See More Headlines
Receive BRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
12/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:BRTX
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$15.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+729.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-18,500,000.00
Net Margins
-13,728.83%
Pretax Margin
-13,728.83%

Debt

Sales & Book Value

Annual Sales
$130,200.00
Book Value
$2.65 per share

Miscellaneous

Free Float
3,660,000
Market Cap
$8.52 million
Optionable
Not Optionable
Beta
58.92
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report














BRTX Stock Analysis - Frequently Asked Questions

Should I buy or sell BioRestorative Therapies stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioRestorative Therapies in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BRTX shares.
View BRTX analyst ratings
or view top-rated stocks.

What is BioRestorative Therapies' stock price target for 2024?

1 Wall Street research analysts have issued 12-month price objectives for BioRestorative Therapies' stock. Their BRTX share price targets range from $15.00 to $15.00. On average, they expect the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 729.0% from the stock's current price.
View analysts price targets for BRTX
or view top-rated stocks among Wall Street analysts.

How have BRTX shares performed in 2023?

BioRestorative Therapies' stock was trading at $2.75 at the start of the year. Since then, BRTX shares have decreased by 34.2% and is now trading at $1.8094.
View the best growth stocks for 2023 here
.

How were BioRestorative Therapies' earnings last quarter?

BioRestorative Therapies, Inc. (OTCMKTS:BRTX) issued its quarterly earnings results on Monday, November, 13th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.04. The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million. BioRestorative Therapies had a negative trailing twelve-month return on equity of 120.47% and a negative net margin of 13,728.83%.

When did BioRestorative Therapies' stock split?

BioRestorative Therapies shares reverse split before market open on Wednesday, October 27th 2021. The 1-4000 reverse split was announced on Wednesday, October 27th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

What other stocks do shareholders of BioRestorative Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioRestorative Therapies investors own include Co-Diagnostics (CODX), Sierra Oncology (SRRA), Tonix Pharmaceuticals (TNXP), Inovio Pharmaceuticals (INO), Vaxart (VXRT), Actinium Pharmaceuticals (ATNM), Inpixon (INPX) and OPKO Health (OPK).

How do I buy shares of BioRestorative Therapies?

Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:BRTX) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -